scholarly journals P60 Daily fluctuations in fatigue severity and C-reactive protein in people with rheumatic diseases

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
Katie L Druce ◽  
David S Gibson ◽  
Keven McEleney ◽  
Stephanie Meleck ◽  
Ben James ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Disease Diagnosis ◽  
Pain Severity ◽  
Ordinal Scale ◽  
C Reactive Protein ◽  
Logistic Regression Models ◽  
Reactive Protein ◽  
Ordered Logistic Regression ◽  
Fatigue Severity ◽  
Active Inflammation

Abstract Background Fluctuations in fatigue severity are common in people with inflammatory (e.g. rheumatoid arthritis (RA)) and non-inflammatory (e.g. fibromyalgia (FM) and osteoarthritis (OA)) rheumatic diseases. We tested whether fluctuations in fatigue in RA, OA and FM were explained by fluctuations in inflammation (C-reactive protein (CRP)), pain and mood. Methods Participants in the GIRAF (Gaining Insight into RheumAtic Fatigue) study used a patient co-configured app to report fatigue severity, pain severity and mood on a 5-point ordinal scale (increasing scores = worse state) twice daily for 7 days. Daily CRP (mg/L) was measured via dried blood spot sampling. Fluctuations in fatigue were calculated as within-day (morning to evening variability) and between-days (morning to morning; evening to evening variability). Multi-level mixed effects ordered logistic regression models tested the relationship between fluctuations in CRP and fatigue over 7 days. The relationships between fluctuations in fatigue, pain and mood were also examined. Models were adjusted for age, sex and disease diagnosis. Results Thirty-eight people (RA:12, OA:13, FM:13) participated and contributed data on 190 (71% of eligible) days. Participants were mostly female (81.6%), with a median age of 56 years. There were no demographic differences between disease groups. Within-day changes in fatigue severity of ≥one point were observed on 97 (51.1%) days and between-days changes were observed on 52% of mornings (92/177 eligible periods) and 49.4% of evenings (85/172 eligible). Fluctuations in pain severity and mood of ≥one point were similarly common (data not shown). Median CRP levels were low (<5mg/L) across all diseases and did not fluctuate substantially between days (change ≥1mg/L:17.5% (33/189) of days). 8 participants (21.1%: RA:4, OA:2, FM:2) had “active inflammation” (CRP>5mg/L) on a total 22 (8.3%) days in the study (range:1-8 days). Fluctuations in CRP were not associated with fluctuations in fatigue (odds-ratio:1.01, 95%CI:0.83-1.22). Fluctuations in pain severity (6.93, 4.68-10.28) and mood (4.58, 3.26-6.45) were associated with fluctuations in fatigue (Table 1). Conclusion Fluctuations in fatigue severity were common in people with rheumatic diseases. Inflammation was low and did not predict fatigue variability. Optimal management should target fatigue independently of inflammatory disease management and may benefit from modification of pain and mood. Disclosures K.L. Druce None. D.S. Gibson None. K. McEleney None. S. Meleck None. B. James None. B. Hellman None. W.G. Dixon None. J. Mcbeth None.

scholarly journals Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results

2020 ◽  
Author(s):  
Barry D Kyle ◽  
Terence A Agbor ◽  
Shajib Sharif ◽  
Usha Chauhan ◽  
John Marshall ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Fecal Calprotectin ◽  
Dependent Manner ◽  
Ascending Colon ◽  
C Reactive Protein ◽  
Concentration Dependent Manner ◽  
Reactive Protein ◽  
Inflammatory Bowel ◽  
Descending Colon ◽  
Active Inflammation

Abstract Background This study aimed to compare fecal calprotectin (FC) levels with other commonly used parameters as part of patient care during evaluation for inflammatory bowel disease (IBD). Methods We recruited adult IBD patients with ulcerative colitis (UC) and Crohn’s disease (CD) and compared the results of the patient’s biopsy results (i.e., inflamed versus noninflamed) for six sites (i.e., ileum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum) with concentrations of C-reactive protein (CRP), total leucocytes and fecal calprotectin (FC). Results We found that FC was significantly elevated in a concentration-dependent manner that correlated with the number of active inflammation sites reported in biopsy. Although CRP and leucocyte measurements trended upwards in line with inflammation reported from biopsy, the results were highly variable and highlighted poor reliability of these biomarkers for indicating IBD inflammation. Conclusions These results strongly suggest that FC correlates best with biopsy reports and is a superior marker than CRP and leucocytes.

scholarly journals The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study

2020 ◽  
Vol 9 (7) ◽  
pp. 2315 ◽  
Author(s):  
Orianne Villard ◽  
David Morquin ◽  
Nicolas Molinari ◽  
Isabelle Raingeard ◽  
Nicolas Nagot ◽  
...  
Keyword(s):  
Inflammatory Responses ◽  
Clinical Course ◽  
Clinical Status ◽  
Plasma Renin ◽  
Ordinal Scale ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein

Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (p < 0.01 and p = 0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome.

scholarly journals Correlation between erythrocyte sedimentation rate and C-reactive protein level in patients with rheumatic diseases

2015 ◽  
Vol 5 ◽  
pp. 243-246 ◽  
Author(s):  
Anna Kotulska ◽  
Magdalena Kopeć-Mędrek ◽  
Anida Grosicka ◽  
Monika Kubicka ◽  
Eugeniusz J. Kucharz
Keyword(s):  
Erythrocyte Sedimentation Rate ◽  
Rheumatic Diseases ◽  
Sedimentation Rate ◽  
Protein Level ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation

scholarly journals Comparative analysis of the systemic inflammatory response in rheumatic diseases

2012 ◽  
Vol 93 (1) ◽  
pp. 12-17
Author(s):  
D V Ivanov ◽  
L A Sokolova ◽  
E Yu Gusev ◽  
L N Kamkina ◽  
N O Plekhanova
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Ankylosing Spondylitis ◽  
Inflammatory Response ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
C Reactive Protein ◽  
Systemic Lupus ◽  
Reactive Protein ◽  
Reactivity Coefficient

Aim. To compare the course of chronic systemic inflammation during various rheumatic diseases. Methods. Examined were three groups of patients: with ankylosing spondylitis - 25 people (20 males and 5 females), with rheumatoid arthritis - 26 people (11 males and 15 females) and with systemic lupus erythematosus - 49 people (3 males and 46 females). The control group included 50 practically healthy individuals (26 males and 24 females). Analyzed were the following parameters: the content of interleukin-6, -8, -10, C-reactive protein. The integral index of the reactivity coefficient was calculated. Results. The level of the studied cytokines was significantly higher in systemic lupus erythematosus, than in ankylosing spondylitis and rheumatoid arthritis, while the content of C-reactive protein was significantly higher in ankylosing spondylitis and rheumatoid arthritis. The values of the reactivity coefficient were also significantly higher in systemic lupus erythematosus. Conclusion. The presence of systemic inflammation was determined in most patients with systemic lupus erythematosus, while ankylosing spondylitis and rheumatoid arthritis were characterized only by mild manifestations of systemic inflammatory response.

scholarly journals Calprotectin predicts mortality after ischemic stroke and is present in the thrombus

2020 ◽  
Author(s):  
Juan Marta-Enguita ◽  
Manuel Navarro-Oviedo ◽  
Idoia Rubio-Baines ◽  
Nuria Aymerich ◽  
Maria Herrera ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Functional Independence ◽  
C Reactive Protein ◽  
Prognostic Information ◽  
Logistic Regression Models ◽  
Neutrophil Lymphocyte Ratio ◽  
Reactive Protein ◽  
Inflammatory Mechanism ◽  
Stroke Centre

Abstract Background- Inflammatory response plays an important role in many processes related to acute ischemic stroke (AIS). Calprotectin (S100A8/S100A9), released by monocytes and neutrophils, is a key protein in the regulation of inflammation and thrombosis. The purpose of this study is to evaluate the association of circulating calprotectin with other inflammatory biomarkers and AIS prognosis, as well as the calprotectin content in stroke thrombi.Methods- Among the 748 patients treated at a comprehensive stroke centre between 2015-2017, 413 patients with confirmed acute ischemic injury were evaluated. Patients with systemic inflammation or infection at onset were excluded. Plasma calprotectin was measured by ELISA in blood samples of AIS patients within the first 24h. Univariate and multivariate logistic regression models were performed to evaluate its association with mortality and functional independence (FI) at 3-months (defined as modified Rankin Scale<2), and intracranial haemorrhage (ICH) after stroke. Further, S100A9 was localized by immunostaining in stroke thrombi (n=44). Results- Higher calprotectin levels were associated with 3-month mortality and ICH, while lower calprotectin levels were documented in patients with 3-month FI. After adjusting for potential confounders, plasma calprotectin levels remained associated with 3-month mortality [OR (95%CI); 3.06, (1.67-5.61)]. Patients with calprotectin≥2.26 µg/mL were 4-times more likely to die [OR 3.98, (1.88-8.41)]. Likewise, Neutrophil-Lymphocyte Ratio (NLR) and C-Reactive Protein (CRP) were also associated with 3-month mortality [OR 1.98, (1.17-3.35); and 1.39, (1.02-1.89) respectively]. A multimarker approach demonstrated that patients with increased calprotectin, CRP and NLR had the poorest outcome with a mortality rate of 42.3% during follow-up. S100A9 protein, as part of the heterodimer calprotectin, was present in all thrombi retrieved from AIS patients. Mean S100A9 content was 3.5% and tended to be higher in patients who died (p=0.09). Moreover, it positively correlated with platelets (Pearson r 0.46, p<0.002); leukocytes (0.45, p<0.01) and neutrophil elastase (0.70, p<0.001) thrombi content. Conclusions- Plasma calprotectin is an independent predictor of 3-month mortality and provides complementary prognostic information to identify patients with poor outcome after AIS. Presence of S100A9 in stroke thrombi suggests a possible inflammatory mechanism in clot formation and further studies are needed to determine its influence in resistance to reperfusion.

Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study

2021 ◽  
Vol 15 (1) ◽  
pp. 5-13
Author(s):  
Kristyna Bubova ◽  
Hana Storkanova ◽  
Sabina Oreska ◽  
Maja Spiritovic ◽  
Barbora Hermankova ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Protein ◽  
Structural Changes ◽  
Bone Marrow Edema ◽  
Heat Shock Protein 90 ◽  
Cross Sectional Study ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Active Inflammation

Aim: Heat shock protein 90 (Hsp90) is a molecular chaperone regulating immune response. We aimed to assess systemic Hsp90 as a biomarker for spondyloarthritis (SpA). Materials & methods: Total of 80 axial SpA (axSpA) and 22 psoriatic arthritis patients and a corresponding number of age- and sex-matched healthy controls (HC) were included. Plasma Hsp90 levels were measured by ELISA. Results: Hsp90 was significantly increased in axSpA patients compared with HC (median interquartile range: 15.7 [10.5–19.8] vs 8.3 [6.6–11.8] ng/ml, p < 0.001). Moreover, Hsp90 was superior to C-reactive protein in differentiating axSpA (and both radiographic axSpA [r-axSpA] and nonradiographic-axSpA) from HC. Hsp90 levels correlated with bone marrow edema of sacroiliac joints in r-axSpA patients (r = 0.594, p = 0.019). Conclusion: Hsp90 could become a biomarker for active inflammation in r-axSpA, and can better distinguish axSpA patients from healthy subjects than C-reactive protein.

scholarly journals Fluorescent fullerene nanoparticle-based lateral flow immunochromatographic assay for rapid quantitative detection of C-reactive protein

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Kyung Mi Park ◽  
Da Jung Chung ◽  
Mijin Choi ◽  
Taejoon Kang ◽  
Jinyoung Jeong
Keyword(s):  
Chemical Species ◽  
Test Strip ◽  
Disease Diagnosis ◽  
Lateral Flow ◽  
Immunochromatographic Assay ◽  
Quantitative Detection ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Diagnosis And Prognosis ◽  
Lateral Flow Immunochromatographic Assay

Abstract A fluorescent fullerene nanoparticle (NP)-based lateral flow immunochromatographic assay (LFIA) was developed for the rapid and quantitative detection of C-reactive protein (CRP) in serum. The polyclonal CRP-antibody-conjugated fullerene NPs were simply prepared by 1-ethyl-3-(3-dimethyllaminopropyl)-carbodiimide hydrochloride coupling after carboxylation of fluorescent fullerene NPs. By applying the CRP-antibody-conjugated fullerene NPs to a lateral flow test strip, quantitative analysis of CRP in serum was possible at a concentration range of 0.1–10 ng/ml within 15 min. We anticipate that this novel fluorescent fullerene NP-based LFIA can be useful for the rapid and accurate sensing of biological and chemical species, contributing to the disease diagnosis and prognosis, environmental monitoring, and food safety.

scholarly journals Investigating the Burden of Chronic Pain: An Inflammatory and Metabolic Composite

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Kimberly T. Sibille ◽  
Ólöf A. Steingrímsdóttir ◽  
Roger B. Fillingim ◽  
Audun Stubhaug ◽  
Henrik Schirmer ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Risk Factor ◽  
Health Behaviors ◽  
Pain Severity ◽  
Maladaptive Behaviors ◽  
C Reactive Protein ◽  
Time Duration ◽  
Reactive Protein ◽  
Related Risk ◽  
Pain Symptoms

Background. Chronic pain is associated with increased morbidity and mortality, predominated by cardiovascular disease and cancer. Investigating related risk factor measures may elucidate the biological burden of chronic pain.Objectives. We hypothesized that chronic pain severity would be positively associated with the risk factor composite.Methods. Data from 12,982 participants in the 6th Tromsø study were analyzed. Questionnaires included demographics, health behaviors, medical comorbidities, and chronic pain symptoms. The risk factor composite was comprised of body mass index, fibrinogen, C-reactive protein, and triglycerides. Chronic pain severity was characterized by frequency, intensity, time/duration, and total number of pain sites.Results. Individuals with chronic pain had a greater risk factor composite than individuals without chronic pain controlling for covariates and after excluding inflammation-related health conditions (p<0.001). A significant “dose-response” relationship was demonstrated with pain severity (p<0.001). In individuals with chronic pain, the risk factor composite varied by health behavior, exercise, lower levels and smoking, and higher levels.Discussion. The risk factor composite was higher in individuals with chronic pain, greater with increasing pain severity, and influenced by health behaviors.Conclusions. Identification of a biological composite sensitive to pain severity and adaptive/maladaptive behaviors would have significant clinical and research utility.

Sign in / Sign up

Export Citation Format

Share Document